Q-omics provides the consensus-scored WDR45B profile across patient tissues and cancer cell-line models. WDR45B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, WDR45B is differentially expressed in 17, with the highest sampling consensus in BLCA. Additionally, WDR45B RNA expression shows 19,956 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, BLCA, and ACC as cancer lineages where WDR45B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WDR45B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WDR45B survival associations across molecular data types. WDR45B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WDR45B RNA expression–survival associations across cancer types. High WDR45B expression shows unfavorable associations in KIRP, KICH, LIHC, ACC, BLCA and ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for WDR45B RNA expression.
This table summarizes WDR45B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for WDR45B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WDR45B shows lower tumor expression in THCA and higher tumor expression in BLCA, COAD, LIHC, LUAD and UCEC. The BLCA box plot shows higher WDR45B RNA expression in tumor versus normal tissue (log2 FC = +0.838, t-test p < 0.001).
This table shows molecular features associated with WDR45B in patient tissues and cancer cell lines. In patient samples, WDR45B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, WDR45B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
